The latest update is out from Amarin ( (AMRN) ).
On April 29, 2025, Amarin Corporation announced it has regained compliance with Nasdaq’s minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market. This compliance was achieved following an adjustment in the ratio of its American Depositary Shares to ordinary shares. The company remains committed to maximizing the global value of its primary product, VASCEPA/VAZKEPA, for cardiovascular disease management.
Spark’s Take on AMRN Stock
According to Spark, TipRanks’ AI Analyst, AMRN is a Neutral.
Amarin’s stock score reflects significant financial and market challenges, notably declining revenues and profitability issues. Technical analysis indicates bearish trends, and valuation metrics are unfavorable. While the company benefits from a strong cash position and global expansion efforts, the impact of U.S. generic competition and increasing net losses are critical concerns.
To see Spark’s full report on AMRN stock, click here.
More about Amarin
Amarin is an innovative pharmaceutical company specializing in cardiovascular disease management. With offices in the United States, Ireland, Switzerland, and other European countries, Amarin focuses on increasing the scientific understanding of cardiovascular risk and advancing treatment options.
YTD Price Performance: 6.39%
Average Trading Volume: 89,706
Technical Sentiment Signal: Buy
Current Market Cap: $213.7M
For detailed information about AMRN stock, go to TipRanks’ Stock Analysis page.